All news

Morgan Stanley cuts Halozyme to Equalweight on valuation

Alpha Vantage · Investing.com Nigeria · · AI-summarised by FinFlash

Morgan Stanley downgraded Halozyme Therapeutics to Equalweight from Overweight, nudging its price target to

Read original source

MS company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.